Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FTIR spectroscopy coupled with chemometrics for evaluating functional food efficacy in an in vitro model of iron deficiency anemia.

Food chemistry·2026
Same author

Chain-length dependent and synergistic prebiotic effects of xylooligosaccharides and xylan on the fecal microbiota of mice in vitro.

International journal of biological macromolecules·2025
Same author

Driveline Relocation and Vacuum-Assisted Closure for Ventricular Assist Device Driveline Infections.

Journal of cardiovascular development and disease·2025
Same author

An ex vivo model for evaluation of prebiotic activity of xylan and xylooligosaccharides.

Food research international (Ottawa, Ont.)·2025
Same author

[MSB-06] Retrospective Cohort Analysis of Ventricular Assist Device Driveline Infections: A Single-Center Experience.

Turk gogus kalp damar cerrahisi dergisi·2025
Same author

[MEP-19] Surgery for A Giant Atherosclerotic Left Main Trifurcation Saccular Coronary Artery Aneurysm.

Turk gogus kalp damar cerrahisi dergisi·2025
Same journal

Association of Protein C, but Not Protein S or Antithrombin With Ischemic Stroke: Bidirectional Two-Sample Mendelian Randomization and Meta-Analysis.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same journal

Risk Prediction Models for Deep Vein Thrombosis in Patients With Spontaneous Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same journal

Efficacy of an Integrated Nursing Protocol for the Management of Postoperative Upper Limb Circulatory Complications Following Transradial Coronary Intervention.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same journal

Dual-Channel Inhibition With Rivaroxaban and Aspirin for Thromboprophylaxis in Patients With Long-Term Inferior Vena Cava Filter Implantation: A Two-Center Cohort Study.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same journal

Association Between TNF-Alpha Levels and Atrial Fibrillation Outcomes: A Systematic Review and Meta-Analysis.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same journal

Interpretation of Prothrombin Time and Activated Partial Thromboplastin Time Mixing Studies Using Predefined Algorithms.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
See all related articles

Related Experiment Video

Updated: Jul 8, 2026

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

MEF2A sequence variants in Turkish population.

Sukru Gulec1, Ahmet Ruchan Akar, Nejat Akar

  • 1Ankara University Biotechnology Institute, Ankara University School of Medicine, Ankara, Turkey.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|December 28, 2007
PubMed
Summary
This summary is machine-generated.

This study investigated the MEF2A gene in premature myocardial infarction (MI) patients. No significant association was found between MEF2A gene variations and premature MI, supporting previous research.

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Experiment Videos

Last Updated: Jul 8, 2026

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Molecular Biology

Background:

  • Myocyte enhancer factor 2 (MEF2) proteins are crucial transcription factors involved in muscle and neuronal development.
  • The MEF2A gene, located on chromosome 15q26, plays a role in various cellular processes.
  • Genetic variations in MEF2A have been investigated for potential links to cardiovascular conditions.

Purpose of the Study:

  • To investigate the association between the MEF2A gene and premature myocardial infarction (MI).
  • To identify potential genetic polymorphisms in MEF2A that may confer risk for early-onset MI.

Main Methods:

  • Screening of MEF2A gene exons 1-8 using single-strand conformation polymorphism (SSCP).
  • Analysis of specific polymorphisms including P279L in exon 7, T>C in intron 10, and a 21-bp deletion in exon 11.
  • Comparison of genetic findings between a premature MI group (n=69, <45 years) and a control group (n=87, >45 years).

Main Results:

  • No abnormal bands were detected by SSCP screening of exons 1-8.
  • A novel T>C polymorphism in intron 10 (145408: T>C) was identified.
  • The P279L polymorphism, the intron 10 T>C polymorphism, and the 21-bp deletion in exon 11 were not found in either group.

Conclusions:

  • The study did not find evidence supporting an association between the investigated MEF2A gene variations and premature MI.
  • The identified intron 10 polymorphism requires further investigation for its functional significance.
  • Current data align with previous studies suggesting MEF2A is not a major genetic contributor to premature MI risk.